drugset / Trial / NCT06333990
Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)
Phase 3
Recruiting
146 enrolled
Foundation for Advancing Veterans' Health Research
Biomedical Research Institute of New Mexico · collabThe University of Texas Health Science Center at San Antonio · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A two site, 2-arm, Phase III randomized pragmatic clinical trial evaluating the effectiveness of quetiapine monotherapy in comparison to Treatment As Usual (TAU) medication management for symptoms experienced by veterans receiving rehabilitation therapy for mild traumatic brain injury (mTBI) and comorbid symptoms of posttraumatic stress disorder (PTSD).
Timeline
- Start
- 2024-07-09
- Primary completion
- 2028-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quetiapine | Small molecule | 200 mg | — |